Gene therapy enters the pharma market: The short story of a long journey

EMBO Molecular Medicine

Volumn 5, Issue 1, 2013, Pages 1-3

  Büning, Hildegard ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; CYCLOSPORIN A; LIPOPROTEIN LIPASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CLINICAL FEATURE; DRUG MARKETING; GENE; GENE MUTATION; GENE THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; LIPOPROTEIN LIPASE GENE; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL;

DEPENDOVIRUS; DRUG APPROVAL; EUROPEAN UNION; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; LIPOPROTEIN LIPASE; MUTATION; RARE DISEASES; RECOMBINANT PROTEINS; TRIGLYCERIDES;

EID: 84871991715     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201202291     Document Type: Note

References (14)

1. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P et al (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270: 475- 480
2. Brunzell JD (1999) Familial lipoprotein lipase deficiency. In GeneReviews™ [Internet], Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds) Seattle (WA): University of Washington
3. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M (2008) Recent developments in adeno-associated virus vector technology. J Gene Med 10: 717- 733
4. Carpentier AC, Frisch F, Labbe SM, Gagnon R, de Wal J, Greentree S, Petry H, Twisk J, Brisson D, Gaudet D (2012) Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 97: 1635- 1644
5. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A (2012) Gene therapy for primary immunodeficiencies: part 1. Curr Opin Immunol 24: 580- 584
6. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N et al (2012a) Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL(S447X)) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther DOI: 10.1038/gt.2012.43
7. Gaudet D, Methot J, Kastelein J (2012b) Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 23: 310- 320
8. 2+-ATPase in patients with advanced heart failure. Circulation 124: 304- 313
9. Kay MA (2011) State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12: 316- 328
10. Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341- 355
11. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES et al (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114: 2077- 2086
12. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, et al (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357- 2365
13. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross C, Aronica E et al (2008) Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28: 2303- 2304
14. Watts G (2012) Gene therapy to be authorised for first time in EU. Br Med J 345: e5009